Compare Panacea Biotech with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs IPCA LABS - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH IPCA LABS PANACEA BIOTECH/
IPCA LABS
 
P/E (TTM) x 15.8 23.2 68.2% View Chart
P/BV x 6.2 8.3 74.2% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PANACEA BIOTECH   IPCA LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
IPCA LABS
Mar-19
PANACEA BIOTECH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3541,042 33.9%   
Low Rs138590 23.4%   
Sales per share (Unadj.) Rs74.6298.6 25.0%  
Earnings per share (Unadj.) Rs6.735.0 19.1%  
Cash flow per share (Unadj.) Rs15.549.4 31.3%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs57.2247.1 23.1%  
Shares outstanding (eoy) m61.25126.35 48.5%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.32.7 120.7%   
Avg P/E ratio x36.823.3 157.9%  
P/CF ratio (eoy) x15.916.5 96.1%  
Price / Book Value ratio x4.33.3 130.2%  
Dividend payout %08.6 0.0%   
Avg Mkt Cap Rs m15,061103,108 14.6%   
No. of employees `0002.313.4 17.2%   
Total wages/salary Rs m1,4717,874 18.7%   
Avg. sales/employee Rs Th1,973.62,807.0 70.3%   
Avg. wages/employee Rs Th635.6585.8 108.5%   
Avg. net profit/employee Rs Th176.8329.0 53.7%   
INCOME DATA
Net Sales Rs m4,56737,732 12.1%  
Other income Rs m45577 7.8%   
Total revenues Rs m4,61238,309 12.0%   
Gross profit Rs m2,0306,901 29.4%  
Depreciation Rs m5401,824 29.6%   
Interest Rs m1,048189 555.5%   
Profit before tax Rs m4865,465 8.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m771,042 7.4%   
Profit after tax Rs m4094,422 9.3%  
Gross profit margin %44.418.3 243.0%  
Effective tax rate %15.919.1 83.1%   
Net profit margin %9.011.7 76.4%  
BALANCE SHEET DATA
Current assets Rs m2,41523,778 10.2%   
Current liabilities Rs m9,07710,975 82.7%   
Net working cap to sales %-145.933.9 -430.0%  
Current ratio x0.32.2 12.3%  
Inventory Days Days65104 62.7%  
Debtors Days Days7166 107.6%  
Net fixed assets Rs m8,33320,368 40.9%   
Share capital Rs m61253 24.3%   
"Free" reserves Rs m3,44330,971 11.1%   
Net worth Rs m3,50431,224 11.2%   
Long term debt Rs m4611,409 32.7%   
Total assets Rs m13,75545,507 30.2%  
Interest coverage x1.530.0 4.9%   
Debt to equity ratio x0.10 291.8%  
Sales to assets ratio x0.30.8 40.0%   
Return on assets %10.610.1 104.6%  
Return on equity %11.714.2 82.4%  
Return on capital %38.717.3 223.4%  
Exports to sales %20.945.9 45.5%   
Imports to sales %8.116.6 49.0%   
Exports (fob) Rs m95417,308 5.5%   
Imports (cif) Rs m3726,266 5.9%   
Fx inflow Rs m1,20317,308 7.0%   
Fx outflow Rs m4676,266 7.4%   
Net fx Rs m73611,042 6.7%   
CASH FLOW
From Operations Rs m1,0494,923 21.3%  
From Investments Rs m-54-1,563 3.4%  
From Financial Activity Rs m-1,011-1,832 55.2%  
Net Cashflow Rs m-201,528 -1.3%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.4 5.3%  
FIIs % 1.3 25.3 5.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.4 135.6%  
Shareholders   10,259 36,892 27.8%  
Pledged promoter(s) holding % 35.1 2.1 1,638.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AUROBINDO PHARMA  ORCHID PHARMA  NOVARTIS  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 7, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS